{"id":"W4390942391","doi":"10.1182/bloodadvances.2023012062","title":"Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Servier; Astellas Pharma; Chugai Pharmaceutical; Agios Pharmaceuticals; Astex Pharmaceuticals; Gilead Sciences; National Comprehensive Cancer Network; Eisai; Syndax Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Celgene; Universität Ulm; AstraZeneca; Pfizer; Amgen","keywords":"Refractory (planetary science); Chemotherapy; Medicine; Oncology; Internal medicine; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008564253,0.000333619,0.001131766,0.0004662696,0.00003349109,0.00006201296,0.0001750253,0.0001734326,0.0008563363],"category_scores_gemma":[0.001460867,0.0002417244,0.000353674,0.0005934364,0.0003449275,0.0003027298,0.000059826,0.0008808251,0.0001537267],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001897305,"about_ca_system_score_gemma":0.0004498176,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003281114,"about_ca_topic_score_gemma":0.00002216492,"domain_scores_codex":[0.9973878,0.0002133738,0.0006823912,0.0006295542,0.0005260027,0.000560876],"domain_scores_gemma":[0.9982339,0.0008703722,0.00008546803,0.0004024397,0.0002013742,0.0002064869],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9555052,0.0008796985,0.0001001062,0.0002759495,0.0004351006,0.002366146,0.001141853,0.00000258673,0.006285571,0.00008155187,0.001949938,0.03097632],"study_design_scores_gemma":[0.9212355,0.00193783,0.00007762897,0.0006789097,0.0002892712,0.0001328125,0.0003660597,0.0004245006,0.006051729,0.0005119919,0.06801438,0.0002793925],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9624187,0.02685332,0.00013958,0.005619014,0.000731816,0.002620916,0.00003239042,0.0001940899,0.001390135],"genre_scores_gemma":[0.985988,0.003802272,0.001735676,0.00170515,0.001302717,0.0007896798,0.0000457934,0.00009503031,0.004535742],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06606444,"threshold_uncertainty_score":0.9857235,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01377240275022055,"score_gpt":0.3323051704801433,"score_spread":0.3185327677299227,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}